Impairment of the PTGS2 activity resulted in decrease of PTGS2 and BCL2 expression and reversal of the resistant NSCLC against the cisplatin, which coincided with the molecular mechanisms as revealed in vitro. The gene discussed is PTGS2; the disease is non-small cell lung carcinoma.